SOURCE-LINKED INTELLIGENCE

ACCELERATING STROKE TREATMENT INNOVATION THROUGH AN AI-ENABLED IN-SILICO NEW APPROACH METHODOLOGY (NAM)

CORDIS · observation · Publication date unknown

ears. inSteps B.V. addresses this crisis through the world’s first high-fidelity In-Silico Thrombectomy Digital Twin Platform. By merging state-of-the-art Finite Element Method (FEM) simulations with Generative AI, the platform creates a revolutionary virtual trial environment powered by a unique database of 4,500 real-world patients. This allows for the synthesis of diverse virtual cohorts to simulate the intricate mechanical interactions between medical devices, vascular anatomy, and human-derived clots with unprecedented precision. By providing a fail-fast mechanism, this data-driven approach allows developers to rapidly iterate and discard suboptimal prototypes before significant capital is committed. This ensures only the most promising technologies advance and de-risks clinical trials, increasing the probability of success and a streamlined path to regulatory approval. This paradigm shift transforms the R&D landscape, slashing design iteration cycles from six weeks to just five days and reducing development expenditures from €5 million to less than €500,000 per project. inSteps

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

300000

unit

EUR